Thelansis

Alpha-1 Antitrypsin Deficiency (AATD) Market Access and Reimbursement Insights Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that...

Alpha-1 Antitrypsin Deficiency (AATD) Emerging Therapy and TPP Insights Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs ...

Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alpha-1 Antitrypsin Deficiency (AATD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the g...

Alpha-1 Antitrypsin Deficiency (AATD) Market Access and Reimbursement Insights Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Alpha-1 Antitrypsin Deficiency (AATD) Overview Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition, often overlooked, characterized by low circulating alpha-antitrypsin (AAT) in the bloodstream. This condition presents as hepatic dysfunction from infancy through adulthood and chronic obstructive lung disease (specifically emphysema or bronchiectasis) in individuals over 30. People with AATD also face an elevated risk of panniculit...

Alpha-1 Antitrypsin Deficiency (AATD) Emerging Therapy and TPP Insights Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Alpha-1 Antitrypsin Deficiency (AATD) Overview Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition, often overlooked, characterized by low circulating alpha-antitrypsin (AAT) in the bloodstream. This condition presents as hepatic dysfunction from infancy through adulthood and chronic obstructive lung disease (specifically emphysema or bronchiectasis) in individuals over 30. People with AATD also face an elevated risk of panniculitis and C-ANCA-positive vasculitis. The expression of these symptoms can vary among individuals and fa...

  Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alpha-1 Antitrypsin Deficiency (AATD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Alpha-1 Antitrypsin Deficiency (AATD) Overview Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition, often overlooked, characterized by low circulating alpha-antitrypsin (AAT) in the bloodstream. This condition presents as hepatic dysfunction from infancy through adulthood and chronic obstructive lung disease (specifically emphysema or bronchiectasis) in individuals over 30. People...

Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition, often overlooked, characterized by low circulating alpha-antitrypsin (AAT) in the bloodstream. This condition presents as hepatic dysfunction from infancy through adulthood and chronic obstructive lung disease (specifically emphysema or bronchiectasis) in individuals over 30. People with AATD also face an elevated risk of panniculitis and C-ANCA-positive vasculitis. The expression of these symptoms can vary among individuals and families. In adults, smoking is the primary factor accelerating the development of chronic obstructive pulmonary disease (COPD). However, nonsmokers with AATD can still develop lung and liver issues and have an average life expectancy. Emphysema in children with AATD is exceedingly rare. AATD-related liver disease, seen in only a small fraction of affected children, typically presents as neonatal cholestasis. The incidence of liver disease increases with age, and adults may develop cirrhosis and f...

 Alpha-1 Antitrypsin Deficiency (AATD) is an autosomal codominant genetic condition that can result in serious lung disease in adults and/or liver disease at any age. AATD occurs when the blood is deficient in a protein called Alpha-1 antitrypsin, or AAT. The liver mainly produces AAT, which primarily protects the lungs from increased protease activity. The responsible gene, SERPINA1, is located on the long arm of chromosome 14 (14q31–32.3). According to Thelansis disease modeling data and literature review estimated, ~78000 patients with AATD in the United States in the year 2020. Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ...